Next-generation genetic neoantigen vaccines
and targeted oncolytic virus for cancer medicine
Successful past experiences are the building block of our new objectives.
Nouscom’s leadership and research team are successful entrepreneurs, who have previously developed innovative candidate vaccines for a range of infectious diseases that include: Malaria (Ewer et al, 2013), Ebola (Stanley et al, 2014; Ewer et al, 2016), Respiratory Syncytial Virus (Taylor et al, 2015; Green et al, 2015), and Hepatitis-C virus (Swadling et al, 2014). The platform technology, originally developed at Okairos, is based on recombinant Adenovirus isolated from non-human great apes (GAd) and Modified Vaccinia Virus Ankara (MVA). The use of viral vectors derived from primates has several advantages, in that they generate potent immune responses, and are much less susceptible to neutralization by pre-existing immunity in humans (Colloca et al, 2012). These vaccine therapies have been evaluated in over 4,000 adult, newborn, and elderly healthy subjects, as well as in patients with chronic infectious diseases, and shown to be safe and efficacious.
The team is now leveraging its experience and expertise in genetic vaccine development to develop a portfolio of novel, safe, and effective neoantigen and oncolytic-based vaccine therapies to target human malignancies and expand the utility of existing immunotherapeutic agents, such as checkpoint inhibitors.